Article
Germline EGFR Mutations and Familial Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Dec 2023
Oxnard Geoffrey R, Chen Ruthia, Pharr Jennifer C, Koeller Diane R, Bertram Arrien A, Dahlberg Suzanne E, Rainville Irene, Shane-Carson Kate, Taylor Kelly A, Sable-Hunt Alicia, Sholl Lynette M, Teerlink Craig C, Thomas Alun, Cannon-Albright Lisa A, Fay André P, Ashton-Prolla Patrícia, Yang Hao, Salvatore Mary M, Addario Bonnie J, Jänne Pasi A, Carbone David P, Wiesner Georgia L, Garber Judy E
Abstract excerpt
PURPOSE: The genomic underpinnings of inherited lung cancer risk are poorly understood. This prospective study characterized the clinical phenotype of patients and families with germline EGFR pathogenic variants (PVs). METHODS: The Investigating Hereditary Risk from T790M study (ClinicalTrials.gov identifier: NCT01754025) enrolled patients with lung cancer whose tumor profiling harbored possible germline EGFR PVs...
Topics
- Humans
- Middle Aged
- Adult
- Lung Neoplasms
- Prospective Studies
- ErbB Receptors
- Mutation
- Protein Kinase Inhibitors
- Germ-Line Mutation